{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:37:31Z","timestamp":1754152651704,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2025.1630080","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:07:55Z","timestamp":1753182475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CB1 receptor and psychosis: friend, foe, or both"],"prefix":"10.3389","volume":"16","author":[{"given":"Jagadeesh S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alejandra","family":"Tangarife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego A.","family":"Rodr\u00edguez-Soacha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Mukunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.81","article-title":"Genetic risk for schizophrenia and psychosis in Alzheimer disease","volume":"23","author":"DeMichele-Sweet","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105900","DOI":"10.1016\/j.neubiorev.2024.105900","article-title":"Genetic overlap between schizophrenia spectrum disorders and Alzheimer's disease: Current evidence and future directions - An integrative review","volume":"167","author":"Ohi","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(96)90035-8","article-title":"Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies","volume":"37","author":"White","year":"1996","journal-title":"Compr Psychiatry"},{"key":"B4","article-title":"The problem with the current high potency THC marijuana from the perspective of an addiction psychiatrist","volume":"115","author":"Stuyt","year":"2018","journal-title":"Mo Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206820109","article-title":"Persistent cannabis users show neuropsychological decline from childhood to midlife","volume":"109","author":"Meier","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.01.026","article-title":"Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction","volume":"57","author":"Caspi","year":"2005","journal-title":"Biol Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.phrs.2021.105938","article-title":"Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment","volume":"174","author":"Stark","year":"2021","journal-title":"Pharmacol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0382-6","article-title":"Cannabinoids and schizophrenia: risks and therapeutic potential","volume":"12","author":"Manseau","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1427","article-title":"In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis","volume":"76","author":"Borgan","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia","volume":"79","author":"Ranganathan","year":"2016","journal-title":"Biol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.44","article-title":"FAAH-\/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration","volume":"35","author":"Falenski","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.v102.9","article-title":"The endocannabinoid system in alzheimer's disease: A network meta-analysis","volume":"102","author":"Liu","year":"2024","journal-title":"J Neurosci Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.01.022","article-title":"A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia","volume":"188","author":"D'Addario","year":"2017","journal-title":"Schizophr Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105357","DOI":"10.1016\/j.phrs.2020.105357","article-title":"Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Delta9-tetrahydrocannabinol-exposed rats","volume":"164","author":"Di Bartolomeo","year":"2021","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107343","DOI":"10.1016\/j.phrs.2024.107343","article-title":"DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use","volume":"208","author":"Di Bartolomeo","year":"2024","journal-title":"Pharmacol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a6bc3b","article-title":"Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia","volume":"29","author":"Schwarcz","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150915","article-title":"Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study","volume":"51","author":"Shelef","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4088\/JCP.23m14791","article-title":"The use of dispensary-obtained tetrahydrocannabinol as a treatment for neuropsychiatric symptoms of dementia","author":"Sawicki","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.009","article-title":"Cannabis and adolescent brain development","volume":"148","author":"Lubman","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140492","article-title":"Type-1 cannabinoid receptor activity during Alzheimer's disease progression","volume":"42","author":"Manuel","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.chc.2022.06.002","article-title":"Impact of adolescent cannabis use on neurocognitive and brain development","volume":"32","author":"Scott","year":"2023","journal-title":"Child Adolesc Psychiatr Clin N Am"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1630080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:07:56Z","timestamp":1753182476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1630080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2025.1630080"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1630080","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1630080"}}